HWAM
NVCR icon

Hennion & Walsh Asset Management’s NovoCure NVCR Stock Holding History

Hennion & Walsh Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$880K Buy
55,201
+787
+1% +$13.1K 0.03% 601
2026
Q2 		$824K Sell
54,414
-477
-0.9% -$7.22K 0.02% 619
2026
Q1 		$598K Buy
54,891
+646
+1% +$8.07K 0.02% 666
2025
Q4 		$701K Buy
54,245
+12,915
+31% +$166K 0.02% 613
2025
Q3 		$534K Buy
41,330
+17,010
+70% +$227K 0.02% 690
2025
Q2 		$433K Buy
+24,320
New +$424K 0.02% 715

Other funds holding NVCR

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Hennion & Walsh Asset Management's NVCR Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its NovoCure (NVCR) stake by 1.4% in Q3 2026, buying an estimated $13.1K and bringing the position to 55,201 shares worth $880K. The position accounts for 0.03% of the portfolio, ranked #601.

Hennion & Walsh Asset Management first reported a position in NVCR in Q2 2025 and has held it in 6 quarters since. 14 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Hennion & Walsh Asset Management held 55,201 shares of NovoCure worth $880K as of Q3 2026.
  • Hennion & Walsh Asset Management bought 787 NovoCure shares in Q3 2026, an estimated $13.1K.
  • NovoCure made up 0.03% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #601 holding.
  • Hennion & Walsh Asset Management first reported a position in NovoCure in Q2 2025 and has held it in 6 quarters since.
  • 14 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.